VCM
CORT icon

Virtue Capital Management’s Corcept Therapeutics CORT Stock Holding History

Virtue Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-47,335
Closed -$1.13M – 297
2021
Q1 		$1.13M Sell
47,335
-4,883
-9% -$130K 0.27% 119
2020
Q4 		$1.37M Buy
+52,218
New +$1.1M 0.34% 86

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Virtue Capital Management's CORT Position: Q2 2021 in Review

Virtue Capital Management sold out of Corcept Therapeutics (CORT) in Q2 2021, closing a stake of 47,335 shares — an estimated $1.13M sold.

Virtue Capital Management first reported a position in CORT in Q4 2020 and held it in 2 quarters. The position peaked at $1.37M in Q4 2020. 199 funds tracked by Wall St. Rank hold CORT as of Q2 2021.

  • Virtue Capital Management reported no remaining Corcept Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Virtue Capital Management sold 47,335 Corcept Therapeutics shares in Q2 2021, an estimated $1.13M.
  • Virtue Capital Management first reported a position in Corcept Therapeutics in Q4 2020 and held it in 2 quarters.
  • Virtue Capital Management's Corcept Therapeutics position peaked at $1.37M in Q4 2020.
  • 199 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2021.

Based on Virtue Capital Management's 13F filing for Q2 2021, filed 15 Jul 2021.